Working capital absorbed US$25.6m as PBT swung to a US$3.0m loss

• Continuing-operations revenue grew 11.2% to US$47.6m; gross margin expanded roughly 94 bps to 37.4%.
• PBT swung from +US$2.6m to -US$3.0m (-215.4%); the 156.7% effective tax rate produced a credit that converted that loss into +US$1.7m NPAT.
• Total NPAT fell 46.9% versus FY21's US$3.2m, reflecting the disposal of the ANZ business (no discontinued-operation contribution this year).
• Operating cash flow eased to US$7.5m from US$9.9m; cash conversion (OCF/EBITDA) fell from 87.6% to 74.3%.
• Net debt fell from US$27.6m to US$11.5m and cash rose from US$6.2m to US$15.2m, assisted by disposal proceeds and a capex cut from US$4.7m to US$1.5m.

The US$25.6m draw is roughly five times the historical mean of US$4.7m, with inventory building US$27.3m. Management cites "record US advanced genetics seedling sales"; if that demand is real and contracted, the build should release in FY23. If it reflects pandemic-era harvest disruption or speculative production, the cash is at risk and the FY22 result is more fragile than it looks.

Reported NPAT is propped up by an unusual tax credit. PBT is the cleaner operating read here and it went backwards from +US$2.6m to -US$3.0m, even as gross margin expanded. The release flags "operating earnings (before other significant items) of US$2.7m" — the gap between that and the PBT loss is the explanation for why the bottom line depends on a 156.7% effective tax rate rather than trading.

Deleveraging is largely a disposal story. The US$16.1m net-debt reduction reflects ANZ disposal proceeds and a US$3.2m capex cut, not operating cash generation, which actually fell. Net debt/EBITDA improving from 2.4x to 1.1x is real, but the underlying business has not yet demonstrated it can self-fund growth at this pace.

The HY22 release referenced reaffirmed guidance for US-GAAP EBITDA in the US$11.3–11.7m range; the FY22 release reports Adjusted US-GAAP EBITDA of US$10.1m (excluding the ANZ business and other significant items), modestly below that range.

Shape context confirms the result is heavily second-half weighted: HY22 continuing revenue of US$4.6m was just 9.7% of full-year US$47.6m, implying ~US$43m in H2. That pattern reflects northern-hemisphere planting seasonality, but it concentrates commercial risk into a short window and amplifies the impact of weather, harvest timing, or operational variances on the year-end number.

Continuing-operations revenue growth (+11.2%) and a ~94 bps gross-margin expansion suggest underlying pricing/mix improvement consistent with the "record advanced genetics seedling sales" commentary. However, operating earnings of US$2.7m did not flow to a positive PBT — "other significant items" and finance costs produced a US$3.0m loss — and the +US$1.7m NPAT depends entirely on a 156.7% tax credit that may not recur.

Cash quality is weaker than the headline ratios suggest. FCF/NPAT of 352.9% looks strong but the denominator is small. Three issues sit underneath: OCF fell US$2.4m year-on-year despite higher revenue; capex at 3.2% of revenue is a sharp pullback from 11.0% in FY21 and may be deferral rather than structural; and the US$25.6m working-capital absorption has tied cash up in inventory that must convert in future periods for the result to validate. ROE of 1.1% is above the supplied historical range (3-period mean -6.4%), but on a thin and tax-assisted earnings base.

This briefing cannot assess the durability of US demand for advanced-genetics seedlings, the strategic position of the remaining US and Brazil businesses post-ANZ disposal, or the probability that the inventory build converts cleanly to revenue in FY23.